Effects of Anticholinergic Drug Withdrawal
on Memory, Regional Cerebral Blood Flow and Extrapyramidal Side Effects in Schizophrenic Patients

It has been suggested that anticholinergic drugs impair immediate memory and working memory in patients with schizophrenia. Opinions remain divided as to the influence of anticholinergic drug withdrawal on the psychopathology and extrapyramidal side effects (EPS) in these patients. In our previous study, regional cerebral blood flow (rCBF) was reduced in all regions of patients taking anticholinergic drugs. Anticholinergic drugs were withdrawn in 21 schizophrenic inpatients. Immediate and verbal working memory, rCBF, psychopathology, and EPS were investigated before and after anticholinergic withdrawal. There was improvement in immediate memory, verbal working memory, and psychopathology, as well as an increase in rCBF after withdrawal from anticholinergic drugs. EPS showed no significant changes. Factors that may predict the improvement of immediate memory after withdrawal of anticholinergic drugs are more severe baseline psychopathology and use of a higher anticholinergic drug dose at baseline. Improvement of working memory may be predicted by a higher baseline rCBF in the left anterior cerebral artery region. Withdrawal from anticholinergics should be considered in schizophrenic patients, and it is important to taper these drugs over at least four weeks.

References

• 1 American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press 4^th ed. 1994
• 2 Baker L A, Cheng L Y, Amara I B. The withdrawal of benztropine mesylate in chronic schizophrenic patients.  Br J Psychiatry. 1983;  143 584-590
• 3 Bech P. Rating Scales for Psychopathology. Health Status and Quality of Life. Springer-Verg, Berlin 1993: 1-43
• 4 Bezchlibnyk-Butler K Z, Remington G J. Anti-Parkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms.  Can J Psychiatry. 1994;  39 74-84
• 5 Borison R L. The role of cognition in the risk - benefit and safety analysis of antipsychotic medication.  Acta Psychiatr Scand Suppl. 1996;  389 5-11
• 6 Caine E D, Weingartner H, Ludlow C L, Cudahy E A, Wehry S. Qualitative analysis of scopolamine-induced amnesia.  Psychopharmacology (Berl). 1981;  74 74-80
• 7 Calev 1987 A, Korin Y, Kugelmass S, Lerer B. Performance of chronic schizophrenics on matched word and design recall tasks.  Biol Psychiatry. 1987;  22 699-709
• 8 Calev A. Recall and recognition in chronic nondemented schizophrenics: use of matched tasks.  J Abnorm Psychol. 1984a ;  93 172-177
• 9 Calev A. Recall and recognition in mildly disturbed schizophrenics: the use of matched tasks.  Psychol Med. 1984b ;  14 425-429
• 10 Caroli F, Littre-Poirier M F, Ginestet D, Deniker P. Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics.  Encephale. 1975;  1 69-74
• 11 de Leon J, Canuso C, White A O, Simpson G M. A pilot effort to determine benztropine equivalents of anticholinergic medications.  Hosp Community Psychiatry. 1994;  45 606-607
• 12 de Oliveira 1 R, Miranda-Scippa A M, de Sena E P, Pereira E L, Ribeiro M G, de Castro-e-Silva E. et al . Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety.  J Clin Pharm Ther. 1996;  21 349-358
• 13 Donlon P T, Stenson R L. Neuroleptic induced extrapyramidal symptoms.  Dis Nerv Syst. 1976;  37 629-635
• 14 Double D B. Unblinding in Trials of the Withdrawal of Anticholinergic Agents in Patients Maintained on Neuroleptics.  J NERV MENT DIS. 1995;  183 599-602
• 15 Double D B, Warren G C, Evans M, Rowlands R P. Efficacy of maintenance use of anticholinergic agents.  Acta Psychiatr Scand. 1993;  88 381-384
• 16 Drachman D A. Memory and cognitive function in man: does the cholinergic system have a specific role?.  Neurology. 1977;  27 783-790
• 17 Drachman D A, Leavitt J. Human memory and the cholinergic system; A relationship to aging?.  Arch Neurol. 1974;  30 113-121
• 18 Fennig S, Levine Y, Naisberg S, Elizur A. The effect of trihexphenidyl (Artane) on memory in schizophrenic patients.  Prog Neuropsychopharmacol Biol Psychiatry. 1987;  11 71-78
• 19 Fletcher P C, Shallice T, Dolan R J. The functional roles of prefrontal cortex in episodic memory. I. Encoding.  Brain. 1998;  121 1239-1248
• 20 Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.  Eur Neuropsychopharmacol. 1996;  6 13-20
• 21 Gardos G, Cole J O, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs.  Am J Psychiatry. 1978;  135 1321-1324
• 22 Green M F, Marshall BD J r, Wirshing W C, Ames D, Marder S R, McGurk S. et al . Does risperidone improve verbal working memory in treatment-resistant schizophrenia?.  Am J Psychiatry. 1997;  154 99-804
• 23 Guy W. Early Clinical Drug Evaluation (ECDEU) assessment manual for psychopharmacology. Nat Inst Ment Health, Rockville 1976
• 24 Hitri A, Craft R B, Fallon J, Sethi R, Sinha D. Serum neuroleptic and anticholinergic activity in relationship to cognitive toxicity of antiparkinsonian agents in schizophrenic patients.  Psychopharmacol Bull. 1987;  23 33-37
• 25 Jellinek T, Gardos G, Cole J O. Adverse effects of antiparkinson drug withdrawal.  Am J Psychiatry. 1981;  138 1567-1571
• 26 Johnson D A, Wright N F. Drug prescribing for schizophrenic out-patients on depot injections. Repeat surveys over 18 years.  Br J Psychiatry. 1990;  156 827-834
• 27 Kane J M. Schizophrenia.  N Engl J Med. 1996;  334 34-41
• 28 Katz I R, Greenberg W M, Barr G A, Garbarino C, Buckley P, Smith D. Screening for cognitive toxicity of anticholinergic drugs.  J Clin Psychiatry. 1985;  46 323-326
• 29 Lavin M R, Rifkin A. Prophylactic antiparkinson drug use: I. Initial prophylaxis and prevention of extrapyramidal side effects.  J Clin Pharmacol. 1991;  31 763-768
• 30 McClelland H A, Blessed G, Bhate S, Ali N, Clarke P A. The abrupt withdrawal of anti-Parkinsonian drugs in schizophrenic patients.  Br J Psychiatry. 1974;  124 151-159
• 31 McEvoy J P, Freter S. The dose-response relationship for memory impairment by anticholinergic drugs.  Compr Psychiatry. 1989;  30 135-138
• 32 Mori K, Teramoto K, Nagao M, Horiguchi J, Yamawaki S. Regional cerebral blood flow in schizophrenia using stable xenon-enhanced computed tomography.  Neuropsychobiology. 1999;  39 117-124
• 33 Nambu K, Suzuki R, Hirakawa K. Cerebral Blood Flow: Measurement with xenon-enhanced dynamic helical CT.  Radiography. 1995;  195 53-57
• 34 Oltmanns T F, Neale J M. Schizophrenic performance when distractors are present. Attentional deficit or diggeneretial task difficulty?.  J Abnormal Psychology. 1975;  84 205-209
• 35 Overall J E, Gorham D R. Brief Psychiatric Rating Scale.  Psychol Reps. 1962;  10 799-812
• 36 Perlick D, Stastny P, Katz I, Mayer M, Mattis S. Memory deficits and anticholinergic levels in chronic schizophrenia.  Am J Psychiatry. 1986;  143 230-232
• 37 Potamianos G, Kellett J M. Anti-cholinergic drugs and memory: the effects of benzhexol on memory in a group of geriatric patients.  Br J Psychiatry. 1982;  140 470-472
• 38 Safer D J, Alien R P. The central effects of scopolamine in man.  Biol Psychiatry. 1971;  3 347-355
• 39 Silver H, Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A Double-blind cross-over study.  Br J Psychiatry. 1995;  166 241-243
• 40 Simpson G M, Angus J WS. A rating scale for extrapyramidal side effects.  Acta Psychiatr Scand. 1970;  212 11-19
• 41 Singh M M, Kay S R, OpIer L A. Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: implications for psychobiological subtyping.  Psychol Med. 1987;  17 39-48
• 42 Sitaram N, Weingartner H, Gillin J C. Human serial learning: enhancement with arecholine and choline impairment with scopolamine.  Science. 1978;  201 274-276
• 43 Spohn H E, Strauss M E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.  J Abnorm Psychol. 1989;  98 367-380
• 44 Stevens A A, Goldman-Rakic P S, Gore J C, Fulbright R K, Wexler B E. Cortical dysfunction in schizophrenia during auditory word and tone working memory demonstrated by functional magnetic resonance imaging.  Arch Gen Psychiatry. 1998;  55 1097-1103
• 45 Sweeney J A, Keilp J G, Haas G L, Hill J, Weiden P J. Relationships between medication treatments and neuropsychological test performance in schizophrenia.  Psychiatry Res. 1991;  37 297-308
• 46 Tamlyn D, McKenna P J, Mortimer A M, Lund C E, Hammond S, Baddeley A D. Memory impairment in schizophrenia: its extent, affiliations and neuropsychological character.  Psychol Med. 1992;  22 101-115
• 47 Tran P V, Dellva M A, Tollefson G D, Beasley CM J r, Potvin J H, Kiesler G M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.  J Clin Psychiatry. 1997;  58 205-211
• 48 Tune L E, Strauss M E, Lew M F, Breitlinger E, Coyle J T. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients.  Am J Psychiatry. 1982;  139 1460-1462
• 49 Van der Linden M, Collette F, Salmon E, Delfiore G, Degueldre C, Luxen A. et al . The neural correlates of updating information in verbal working memory.  Memory. 1999;  7 549-560
• 50 Yamashita T, Nagatsugu Y, Ishihara H, Shiroyama Y, Wakuta Y, Kashiwagi S. Comparison of Xe-CT/CBF and quantitative ECD-SPECT.  Acta Neurol Scand Suppl. 1996;  166 6-9
• 51 Yonas H, Pindzola R P, Johnson D W. Xenon/computed tomography cerebral blood flow and its use in clinical.  Neurosurg Clin N Am. 1996;  7 605-616